Etude clinique de phase III, randomisée, contrôlée par placebo évaluant la sécurité d’emploi et l’efficacité de la radiochirurgie (SBRT) avec ou sans Pembrolizumab (MK-3475) chez des patients atteints d’un cancer du poumon non à petites cellules de stade I ou IIA inopérable (Keynote-867)

A Phase 2, Multi-center, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy

A Phase 2, Multi-center, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy

A Phase II Single-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior 1st to 3rd Generation EGFR-tyrosine Kinase Inhibitor Therapy

Immunothérapies (PD-L1) et irradiation concomitante sur des sites tumoraux variés dans les cancers du poumon avancé non à petites cellules